Midatech Pharma Plc Deuda/Patrimonio neto
¿Qué es el Deuda/Patrimonio neto de Midatech Pharma Plc?
El Deuda/Patrimonio neto de Midatech Pharma Plc es 0.75
¿Cuál es la definición de Deuda/Patrimonio neto?
La relación deuda / patrimonio neto es una relación financiera que indica la proporción relativa del capital contable y la deuda utilizada para financiar los activos de una empresa.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Deuda/Patrimonio neto de compañías en Sector Health Care en LSE en comparadas con Midatech Pharma Plc
¿Qué hace Midatech Pharma Plc?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Empresas con deuda/patrimonio neto similar a Midatech Pharma Plc
- Hindustan Tin Works tiene Deuda/Patrimonio neto de 0.75
- Signaux Girod S.A tiene Deuda/Patrimonio neto de 0.75
- SFC AG tiene Deuda/Patrimonio neto de 0.75
- Yamana Gold tiene Deuda/Patrimonio neto de 0.75
- Yamana Gold tiene Deuda/Patrimonio neto de 0.75
- Hydrofarm tiene Deuda/Patrimonio neto de 0.75
- Midatech Pharma Plc tiene Deuda/Patrimonio neto de 0.75
- Marathon Oil tiene Deuda/Patrimonio neto de 0.75
- Quarterhill tiene Deuda/Patrimonio neto de 0.75
- Fidelity National Information Services tiene Deuda/Patrimonio neto de 0.75
- Fidelity National Information Services tiene Deuda/Patrimonio neto de 0.75
- Applied Industrial Technologies tiene Deuda/Patrimonio neto de 0.75
- Panama Petrochem tiene Deuda/Patrimonio neto de 0.75